DataMeds AI (NASDAQ: MEDS) faces $19.5M deficit, 1-for-50 reverse split
Rhea-AI Filing Summary
DataMeds AI, Inc. reported second quarter 2026 net revenues of $1.78 million, down sharply from $7.79 million a year earlier, but up 14% sequentially from the first quarter, exceeding internal projections. Gross profit was $0.18 million, and the company recorded an operating loss of $7.35 million.
After $11.02 million in net other expense, including an $8.88 million loss on extinguishment of debt, net loss for the quarter was $18.36 million, or $7.13 per share. Total assets were $32.76 million against liabilities of $52.26 million, resulting in a stockholders’ deficit of $19.50 million.
The company highlighted a pending Datavault Transaction, a planned September 2026 launch of the Health Lives Here app with NFL Alumni Health targeting GLP‑1 users, a $6.5 million capital raise, restructuring of $14.5 million in debt toward a preferred equity swap, a 1-for-50 reverse stock split, and new lock-up agreements covering about 49% of outstanding shares.
Positive
- Sequential revenue up 14% to $1.78 million, exceeding management projections and indicating early traction in the restructured business.
- $6.5 million in new funding and restructuring of $14.5 million of debt toward a preferred equity swap strengthen liquidity and capital structure.
- Six‑month net loss improved to $26.11 million from $39.10 million year over year, a reduction of more than 30% in cumulative losses.
Negative
- Quarterly revenue fell from $7.79 million to $1.78 million year over year, a decline of more than 70%, signaling significant business contraction.
- Net loss for Q2 2026 widened to $18.36 million from $6.67 million, driven by an $8.88 million loss on extinguishment of debt and higher expenses.
- Balance sheet shows a stockholders’ deficit of $19.50 million with total liabilities of $52.26 million, underscoring financial risk despite recent financing.
- A 1-for-50 reverse stock split was implemented to partially address Nasdaq delisting risk, highlighting ongoing listing-compliance pressures.
Filing Explained
June 30 cash was $2,456,373; the results exhibit was furnished rather than filed, and quarterly operating cash outflow was $2,894,199.
Form 8-K reports specified material events; here, the company furnished its second-quarter results and business update through Exhibit 99.1. The filing says that this information is not deemed “filed” under Section 18 or incorporated by reference into other filings, except as expressly stated.
As of
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Net Revenues: $1,779,860
Q2 2025 Net Revenues: $7,790,865
Q2 2026 Net Loss: $18,363,225
+5 more
8 metrics
Q2 2026 Net Revenues
$1,779,860
Three months ended June 30, 2026
Q2 2025 Net Revenues
$7,790,865
Three months ended June 30, 2025, prior-year comparator
Q2 2026 Net Loss
$18,363,225
Three months ended June 30, 2026
Q2 2026 Net Loss per Share
$7.13
Basic and diluted, three months ended June 30, 2026
Loss on Extinguishment of Debt
$8,881,694
Other expense in quarter ended June 30, 2026
New Funding Raised
$6,500,000
Capital raised in June 2026 to support turnaround
Debt Restructured
$14,500,000
Pre-existing debt restructured toward preferred equity swap
Stockholders’ Deficit
$19,504,231
Total stockholders’ equity (deficit) as of June 30, 2026
Key Terms
reverse stock split, lock-up agreements, loss on extinguishment of debt, health data tokenization, +1 more
5 terms
reverse stock split financial
"1:50 reverse split in May 2026 implemented to partially address NASDAQ delisting risk"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
lock-up agreements financial
"Holders of 1,533,930 common shares...have entered into lock-up agreements"
A lock-up agreement is a contract that prevents company insiders—founders, employees, and early investors—from selling their shares for a set period after a public stock offering. It matters to investors because it keeps a large block of shares off the market temporarily; when the lock-up ends, those holders can sell and this increased supply can cause the stock price to fall, similar to a timed release that suddenly opens a valve.
loss on extinguishment of debt financial
"Loss on extinguishment of debt | | | (8,881,694 | )"
Loss on extinguishment of debt is the accounting hit a company records when it retires or restructures a loan or bond for an amount that exceeds the debt’s recorded value—like paying more than the remaining balance to settle a loan early. It matters to investors because it reduces reported profit and can use cash, but may also cut future interest costs or signal financial stress; understanding it helps assess earnings quality and balance-sheet strength.
health data tokenization technical
"patent protection on healthcare data tokenization and monetization"
GLP-1 agonist medications medical
"targeting patients on or contemplating taking GLP-1 agonist medications in rural communities"
Earnings Snapshot
Net revenues (Q2 2026 vs Q2 2025): $1,779,860 vs $7,790,865
Quarter and six months ended June 30, 2026
Net revenues (Q2 2026 vs Q2 2025)
$1,779,860 vs $7,790,865
Down more than 70% year over year; up 14% sequentially vs Q1 2026 per company
Net loss (Q2 2026 vs Q2 2025)
$18,363,225 vs $6,672,464
Net loss increased by roughly 175% year over year
Net revenues (six months 2026 vs 2025)
$3,339,423 vs $18,654,308
Revenue declined by more than 80% for the first half year over year
Net loss (six months 2026 vs 2025)
$26,105,822 vs $39,103,367
Net loss decreased by more than 30% for the first half year over year
Net loss per share (Q2 2026 vs Q2 2025)
$7.13 vs $5.40
Loss per share widened by about 32% year over year
FAQ
How did DataMeds AI (MEDS) perform financially in Q2 2026?
DataMeds AI reported Q2 2026 net revenues of $1.78 million and a net loss of $18.36 million. Revenue fell sharply year over year from $7.79 million, while net loss widened significantly, largely due to an $8.88 million loss on extinguishment of debt and higher operating expenses.
What were the key revenue trends for DataMeds AI (MEDS) in 2026 so far?
For the first half of 2026, DataMeds AI generated $3.34 million in revenue versus $18.65 million a year earlier. However, Q2 2026 revenue of $1.78 million rose 14% sequentially versus Q1 2026, exceeding management projections and suggesting some stabilization after a steep year‑over‑year decline.
What major capital and debt actions did DataMeds AI (MEDS) take in 2026?
DataMeds AI raised $6.5 million in new funding and restructured $14.5 million of pre‑existing debt to provide a path to a preferred equity swap. The company also recorded an $8.88 million loss on extinguishment of debt, reflecting the cost of these capital structure changes.
What strategic initiatives and product launches is DataMeds AI (MEDS) planning?
The company plans to launch the Health Lives Here consumer app with NFL Alumni Health in September 2026, targeting GLP‑1 users in rural communities. It also expects to launch Forzet medical food, close the Datavault Transaction, and further integrate AI, blockchain and telemedicine capabilities.
What does the balance sheet of DataMeds AI (MEDS) look like as of June 30, 2026?
As of June 30, 2026, DataMeds AI reported $32.76 million in total assets and $52.26 million in total liabilities. This resulted in a stockholders’ deficit of $19.50 million, reflecting substantial accumulated losses and highlighting continued financial and capital-structure challenges.
AI-generated analysis. How Rhea-AI works. Not financial advice.
